在癌症中准肌酸和肌酸激酶:探索潜在的治疗策略
Mahla Abdollahzadeh1, Razieh Ghodsi1,2, Zhila Taherzadeh3,4
1Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Current drug targets
|July 2, 2025
概括
肌酸激酶 (CKs) 对癌细胞能量至关重要. 抑制CKs,它们的载体或相关反应,通过破坏癌细胞生物能量,为瘤学提供了一个有前途的治疗策略.
科学领域:
- 生物化学 生物化学
- 细胞生物能学 细胞生物能学
- 酶学 是一种酶学.
背景情况:
- 肌酸激酶 (CKs) 是通过ATP-肌酸系统调节细胞能量的关键酶.
- 这种能量系统对于高能耗的过程至关重要,特别是在快速增殖的癌细胞中.
- CKs在支持瘤生长和转移方面发挥着重要作用,突出显示它们是治疗点.
研究的目的:
- 审查在癌症中破坏肌酸能量生产周期的策略.
- 分析现有的CK抑制剂的结构-活性和结构-性质关系.
- 引导开发用于瘤学应用的新型,强效和选择性CK抑制剂.
主要方法:
- 对针对肌酸运输体 (SLC6A8) 的研究策略的审查,以限制细胞内肌酸的可用性.
- 对针对CK活性的直接酶抑制策略的分析.
- 检查旨在破坏CK平衡的反向反应 (脂蛋白转化为肌酸) 的方法.
主要成果:
- 目前CK抑制剂的概述,详细说明它们的结构-活性和结构-性质关系.
- 确定关键的研究领域,以破坏肌酸激酶能量通路.
- 强调了解抑制剂关系的必要性,以开发改进的治疗方法.
结论:
- 通过各种策略破坏CK能量循环,在瘤学中呈现出一个可行的治疗途径.
- 对结构-活性和结构-特性关系的深入理解对于设计有效的CK抑制剂至关重要.
- 对CK抑制的进一步研究有望为开发新的抗癌治疗提供希望.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.1K
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
15.0K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Electron Transport Chain: Complex I and II
15.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.1K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
